Eli Lilly files complaint about unapproved versions of tirzepatide
Eli Lilly is experiencing problems with the sale of unapproved versions of active pharmaceutical ingredient tirzepatide used in diabetes drug Mounjaro. Novo has previously reported similar problems.
US pharmaceutical company Eli Lilly, a direct competitor of Danish Novo Nordisk, announced in a brief statement that the company has filed a complaint with the US International Trade Commission to prevent companies from importing, selling or distributing unapproved versions of the active ingredient, tirzepatide.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Eli Lilly sues clinics for selling fake diabetes drug
For subscribers
